At AACR, Ultima Genomics presented early TRACERx MRD results using its ppmSeq technology, describing ultra-sensitive ctDNA detection in plasma at low single-digit parts-per-million. The program is nested within Cancer Research UK’s long-running TRACERx effort, which sequences multi-region and multi-time-point tumor data across more than 800 lung cancer patients. The company said an early validation pilot tested ppmSeq across 50 plasma samples, using tumor-specific variants identified from prior whole genome sequencing, with the goal of improving analytical sensitivity for minimal residual disease monitoring. Charles Swanton of The Francis Crick Institute delivered the TRACERx-linked presentation. Collaborator data was also described, including an independent analytical study from Labcorp evaluating an assay developed in coordination with ppmSeq technology across multiple tumor types. Labcorp’s pre-surgical, treatment-naive donor sample analysis reportedly showed specificity exceeding 99%. If these performance claims translate clinically at scale, MRD workflows could become more actionable in NHS-scale deployment, improving earlier detection of recurrence signals beyond imaging.